Generic name: cabergoline
Dosage form: Tablets
Medically reviewed on January 18, 2018.
The recommended dosage of DOSTINEX Tablets for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient's serum prolactin level. Before initiating treatment, cardiovascular evaluation should be performed and echocardiography should be considered to assess for valvular disease.
Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient's response to each dosage level. If the patient does not respond adequately, and no additional benefit is observed with higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered. Patients receiving long term treatment with DOSTINEX should undergo periodic assessment of their cardiac status and echocardiography should be considered.
After a normal serum prolactin level has been maintained for 6 months, DOSTINEX may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when treatment with DOSTINEX should be reinstituted. The durability of efficacy beyond 24 months of therapy with DOSTINEX has not been established.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Dostinex (cabergoline)
- Dostinex Side Effects
- During Pregnancy or Breastfeeding
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- En Español
- 12 Reviews
- Drug class: prolactin inhibitors